Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus alfentanil vs propofol plus sufentanil for anesthesia induction in children with congenital heart disease
ChiCTR2400081101Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in Cardiovascular Malformation (CVM) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Incidence of hypotension. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on ChiCTR2400081101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081101.